Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 1/20 | 0.57 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.57 |
| ▸ | APLNR | P35414 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL626051 | 0.87 | TAAR1 (0.73) | ADRA1ATAAR1APLNRCYP1A2 | |
| SCHEMBL30107392 | 0.87 | APLNR (0.63) | ADRA1ATAAR1APLNRCYP1A2CA12 | |
| SCHEMBL22939735 | 0.84 | APLNR (0.56) | APLNR | |
| Methylamine SCHEMBL27659015 | 0.83 | HTR2A (0.54) | APLNR | |
| SCHEMBL4862695 | 0.83 | APLNR (0.54) | ADRA1ATAAR1APLNRCA12CA1 | |
| SCHEMBL30358658 | 0.83 | MEN1 (0.56) | APLNR | |
| SCHEMBL1171776 | 0.83 | MEN1 (0.56) | APLNR | |
| SCHEMBL8160809 | 0.83 | APLNR (0.54) | ADRA1ATAAR1APLNRCA12CA1 | |
| SCHEMBL9417780 | 0.82 | APLNR (0.58) | ADRA1ATAAR1APLNRCA12CA1 | |
| SCHEMBL13528991 | 0.81 | APLNR (0.53) | ADRA1ATAAR1APLNRCA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7368450-B2 | Antihistamines; bronchodilators; antiinflammatory agents; inflammatory bowel disorders | PARION SCIENCES, INC. (US) | 2008-05-06 | — | — | US | disclosed |
| EP-1485359-B1 | SODIUM CHANNEL BLOCKERS | PARION SCIENCES INC (US) | 2007-12-05 | — | — | EP | disclosed |
| US-7247636-B2 | Phenolic guanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2007-07-24 | — | — | US | disclosed |
| US-7241766-B2 | Methods of using phenolic guanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2007-07-10 | — | — | US | disclosed |
| US-7192959-B2 | Antihistamines; antiinflammatory agents; bronchodilator agents; inflammatory bowel disorders; psoriasis | PARION SCIENCES, INC. (US) | 2007-03-20 | — | — | US | disclosed |
| US-7192958-B2 | Sodium channel blockers | PARION SCIENCES, INC. (US) | 2007-03-20 | — | — | US | disclosed |
| EP-1485359-A4 | SODIUM CHANNEL BLOCKERS | PARION SCIENCES INC (US) | 2006-03-22 | — | — | EP | disclosed |
| US-6858614-B2 | Phenolic guanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2005-02-22 | — | — | US | disclosed |
| EP-1485359-A2 | SODIUM CHANNEL BLOCKERS | Johnson, Michael R. (US) | 2004-12-15 | — | — | EP | disclosed |
| US-20040204424-A1 | Such as 4-(4-hydroxyphenyl)butylamidino-3,5-diamino-6-chloropyrazinecarboxamide hydrochloride; time-release agents; for therapy of chronic bronchitis, emphysema, cystic fibrosis, and eye disorders | PARION SCIENCES, INC. | 2004-10-14 | — | — | US | disclosed |
| US-20040198745-A1 | Sodium channel blockers | PARION SCIENCES, INC. (US) | 2004-10-07 | — | — | US | disclosed |
| US-20040198746-A1 | Sodium channel blockers | PARION SCIENCES, INC. (US) | 2004-10-07 | — | — | US | disclosed |
| US-20040198747-A1 | Sodium channel blockers | PARION SCIENCES, INC. (US) | 2004-10-07 | — | — | US | disclosed |
| US-20040198744-A1 | Methods of using phenolic guanidine sodium channel blockers | PARION SCIENCES, INC. | 2004-10-07 | — | — | US | disclosed |
| US-20030195160-A1 | Sodium channel blockers | CYFI, INC. | 2003-10-16 | — | — | US | disclosed |
| WO-2003070184-A2 | SODIUM CHANNEL BLOCKERS | JOHNSON MICHAEL R (US) | 2003-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204424-A1 | Such as 4-(4-hydroxyphenyl)butylamidino-3,5-diamino-6-chloropyrazinecarboxamide hydrochloride; time-release agents; for therapy of chronic bronchitis, emphysema, cystic fibrosis, and eye disorders | CFTR, TRPC4, TRPC5 | ADRA1A 599/4885TAAR1 1320/4885APLNR 1059/4885 |
| US-20030195160-A1 | Sodium channel blockers | HCN4, SCN2B, SCN5A | ADRA1A 307/4885TAAR1 1082/4885APLNR 854/4885 |
| US-20040198747-A1 | Sodium channel blockers | HCN4, SCN2B, SCN5A | ADRA1A 307/4885TAAR1 1082/4885APLNR 854/4885 |
| US-20040198745-A1 | Sodium channel blockers | SCN2B, SCN4A, SCN1B | ADRA1A 150/4885TAAR1 634/4885APLNR 1503/4885 |
| US-20040198744-A1 | Methods of using phenolic guanidine sodium channel blockers | KCNH2, KCNH3, KCNJ1 | ADRA1A 250/4885TAAR1 1072/4885APLNR 1484/4885 |
| US-20040198746-A1 | Sodium channel blockers | HCN4, SCN2B, SCN5A | ADRA1A 307/4885TAAR1 1082/4885APLNR 854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.